A team of scientists has identified an enzyme called PurF as a new drug target for tuberculosis, offering a fresh line of ...

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA ...

This figure illustrates three key applications of AI in antimicrobial drug development: (1) target identification and validation, including novel target discovery, affinity prediction, multi-target ...

Indiana University School of Medicine scientists have identified a promising drug target for Alzheimer's disease. The team found that removing an enzyme from neurons in the brain substantially reduces ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how neg-entropy is the true drug target for chronic diseases. Molecular mechanisms of chronic diseases are complicated, and ...

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...

Lilly licenses Insilico's AI drug discovery platform in a deal worth up to $2.75B, signaling a shift in how novel ...

The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (ILMN) today introduced the world's ...

SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through ...